Avinger - AVGR Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AVGR shares.
View AVGR analyst ratings or view top-rated stocks.

1 Wall Street research analysts have issued 1 year price targets for Avinger's shares. Their AVGR share price forecasts range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 620.0% from the stock's current price.
View analysts price targets for AVGR or view top-rated stocks among Wall Street analysts.

Avinger's stock was trading at $9.00 at the start of the year. Since then, AVGR shares have decreased by 86.1% and is now trading at $1.25.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our AVGR earnings forecast.

Avinger, Inc. (NASDAQ:AVGR) released its quarterly earnings results on Thursday, November, 11th. The medical device company reported ($1.20) earnings per share for the quarter, topping the consensus estimate of ($1.40) by $0.20. The medical device company had revenue of $2.37 million for the quarter, compared to the consensus estimate of $2.52 million. Avinger had a negative trailing twelve-month return on equity of 244.04% and a negative net margin of 212.53%. During the same period last year, the business earned ($1.60) earnings per share.

Shares of Avinger reverse split on the morning of Tuesday, March 15th 2022. The 1-20 reverse split was announced on Tuesday, March 15th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), OrganiGram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).

(AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company acted as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

Avinger's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (8.99%), Vanguard Group Inc. (1.85%) and Perkins Capital Management Inc. (0.67%). Insiders that own company stock include Himanshu Patel, James Cullen, Jeffrey M Soinski and Mark Weinswig.
View institutional ownership trends.

Shares of AVGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AVGR stock can currently be purchased for approximately $1.25.

Avinger (NASDAQ:AVGR) has a market capitalization of $9.30 million and generates $10.13 million in revenue each year. The medical device company earns $-17,410,000.00 in net income (profit) each year or ($5.30) on an earnings per share basis.

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.avinger.com. The medical device company can be reached via phone at (650) 241-7900, via email at info@dawson3d.com, or via fax at 800-229-2696.